OREANDA-NEWS  On 06 November was announced, that JSC Grindeks forecasts that the year 2008 will end successfully and the turnover in the amount of LVL 64 million will be reached. Such a result will be obtained due to successful business activity in Russia, the rest CIS states and product sales in other world markets.

In order to achieve the current turnover dynamics also in the future, Chairman of the Council of JSC Grindeks Kirovs Lipmans emphasizes: “The market strategy of Grindeks has justified itself, therefore we will concentrate our activity on both, the existing markets and the new, prospective market acquisition such as China and Turkey, as well as entering smaller South Asian markets, for example, Vietnam also in the future.”

Upon registering Mildronate and implementation of business activity in China, Kirovs Lipmans, who has just returned from a business visit in Beijing sees further development opportunities of the company: “If everything will take place as it is currently planned, a manufacturing joint company could be established in the future, as well as registration of the second brand product of Grindeks Ftorafur started in China.”

In order to maintain the previous development rates of the company within a long term, Grindeks will annually invest 9-11% of the turnover in research and development also in the future. Chairman of the Council remarks: “Competition in the pharmacy sector is intense, therefore our strategy must be aggressive and the plans – ambitious. Purposeful investments must be made in research and technologies so that Grindeks duplicated and even triplicated the turnover within the next five years – it must be thought about both, development of new products and continuous improvement of infrastructure. That is our perspective.”